
BioSerenity develops connected medical solutions to help diagnose and monitor patients with chronic diseases in neurology, sleep disorders and cardiology. We use physiological sensors, an IoT platform, apps and A.I. to detect digital biomarkers. We work with more than 200 hospitals in Europe and help diagnose over a hundred thousand patients per year. Our headquarter is in Paris, France.

BioSerenity develops connected medical solutions to help diagnose and monitor patients with chronic diseases in neurology, sleep disorders and cardiology. We use physiological sensors, an IoT platform, apps and A.I. to detect digital biomarkers. We work with more than 200 hospitals in Europe and help diagnose over a hundred thousand patients per year. Our headquarter is in Paris, France.
Core offering: Connected medical devices, AI software and telemedicine for neurology, sleep and cardiology diagnostics
Founded / HQ: Founded 2014; headquarters in Paris, France (also presence in Boston, MA)
Customers / scale: Works with ~200 hospitals/clinics and ~9,000 physicians; >100,000 patients diagnosed per year (company figures)
Recent financing: €24M investment from Jolt Capital announced Nov 2023
Regulatory status: Devices with FDA clearance and CE certification reported
Remote diagnosis and monitoring of chronic neurological, sleep and cardiac conditions.
2014
Medical technology / Digital health
€24M
Investment announced to support international development and AI deployment; leadership update noted appointment of new CEO.
Listed as a corporate round led by Scor on company/third-party profiles.
Listed as a corporate round on third-party profiles.
“Jolt Capital and Scor are among disclosed investors; company reported multiple rounds and nine investors on third-party profiles.”
| Company |
|---|